美国批准的镰状细胞病基因疗法每个疗程的费用高达 310 万美元，这可能会限制其获得机会。 Genetic therapies for sickle cell disease, approved in the US, cost up to $3.1M per course, potentially limiting access.

基因疗法改变了镰状细胞病患者的生活，在多年的痛苦之后创造了“生命的奇迹”。 Genetic therapies have transformed the lives of sickle cell patients, providing a "miracle of life" after years of pain. 这些治疗方法已在美国获得批准，但价格昂贵，每个疗程的费用高达 310 万美元。 These treatments, which have been approved in the US, are expensive, with costs reaching up to $3.1 million per course. 镰状细胞病 (SCD) 影响着美国约 10 万人和全球 2000 万人，其中大多数患者是黑人。 Sickle cell disease (SCD) affects around 100,000 people in the US and 20 million worldwide, with the majority of patients being Black. 高昂的费用可能会限制其他患者获得这些改变生活的治疗。 The high cost could limit access to these life-changing treatments for other patients.